Phathom Pharmaceuticals, Inc.
https://www.phathompharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Phathom Pharmaceuticals, Inc.
Keeping Track: AZ’s Busy Oncology Biz, Phathom’s Voquezna Approval, And A Trio Of Complete Response Letters
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Finance Watch: Bausch + Lomb Completes Split From Bausch Health Via IPO
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Phathom’s First Approval Of Voquezna Expected To Lay Ground For Larger Indications
The Takeda spinout got FDA approval of its acid blocker as combination therapy for H. pylori infections, but the bigger opportunities await in erosive esophagitis and non-erosive reflux disorder.
Keeping Track: Marinus’ Ztalmy Continues US FDA’s Orphan Streak; AZ Gets Adjuvant Nod For Lynparza, Fasenra CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
- Industry
- Biotechnology
- Pharmaceuticals